A detailed history of Walleye Capital LLC transactions in Crispr Therapeutics Ag stock. As of the latest transaction made, Walleye Capital LLC holds 45,200 shares of CRSP stock, worth $2.33 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
45,200
Previous 48,400 6.61%
Holding current value
$2.33 Million
Previous $3.3 Million 25.99%
% of portfolio
0.0%
Previous 0.01%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$51.17 - $68.18 $7,368 - $9,817
144 Added 24.32%
736 $39,000
Q1 2024

May 15, 2024

BUY
$60.67 - $89.12 $35,916 - $52,759
592 New
592 $40,000
Q4 2022

Feb 14, 2023

BUY
$39.19 - $65.67 $1.27 Million - $2.12 Million
32,358 New
32,358 $1.32 Million
Q4 2019

Feb 14, 2020

SELL
$36.68 - $73.13 $57,037 - $113,717
-1,555 Closed
0 $0
Q3 2019

Nov 14, 2019

BUY
$40.99 - $52.56 $63,739 - $81,730
1,555 New
1,555 $64,000

Others Institutions Holding CRSP

About CRISPR Therapeutics AG


  • Ticker CRSP
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 78,009,296
  • Market Cap $4.03B
  • Description
  • CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....
More about CRSP
Track This Portfolio

Track Walleye Capital LLC Portfolio

Follow Walleye Capital LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Walleye Capital LLC, based on Form 13F filings with the SEC.

News

Stay updated on Walleye Capital LLC with notifications on news.